Progyny is showing strong revenue growth and profitability, has an excellent balance sheet, no debt, and improving margins.

Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are ...

Another notable valuation metric for PGNY is its P/B ratio of 4.67. Investors use the P/B ratio to look at a stock's market ...

Progyny, Inc. offers fertility benefits management, growing eligible members to 7.2 million and posting steady revenue and ...

Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, ...

Progyny reported record first‑quarter 2026 revenue of $328.5 million on May 7, 2026, with growth in both fertility and pharmacy benefit services despite the loss of a large client that contributed $31 ...

Progyny is set to benefit from several structural tailwinds, including catalysts that should help it court more clients, according to Wells Fargo.

Progyny, Inc. has announced its acquisition of BenefitBump, a program that navigates parental leave benefits for new and growing families. This move enhances Progyny's suite of offerings in fertility ...